A lawsuit over generic versions of Allergan PLC’s Alzheimer’s drug Namenda XR (memantine extended-release) is challenging how FDA determines whether an abbreviated new drug application (ANDA) sponsor has forfeited generic marketing exclusivity.
In a Jan. 27 complaint, Amneal Pharmaceuticals LLC asks the US District Court for the District of...






